Of all included studies in which the added benefit of anti-EGFR to chemotherapy was evaluated, one second-line and three first-line studies retrospectively assessed the effect in a RAS WT group (n = 1464 patients), excluding patients whose tumor harbored additional mutations in KRAS exon 3–4 and NRAS exon 2–4 [15–17, 20]. The gene discussed is KRAS; the disease is neoplasm.